Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.4 to v3.6.5. This indicates a new version of the site.
    Difference
    0.0%
    Check dated 2026-08-11T18:00:05.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The page footer now includes a new Revision: v3.6.4 tag, replacing the previous Revision: v3.6.3 tag, signaling the latest page revision.
    Difference
    0.0%
    Check dated 2026-07-28T13:45:37.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    The revision label on the page was updated to v3.6.3, indicating a newer build of the site.
    Difference
    0.0%
    Check dated 2026-06-30T01:41:20.000Z thumbnail image
  6. Check
    70 days ago
    Change Detected
    Summary
    Added recruitment notice 'No longer looking for participants' and new help/navigation sections including How to Read a Study Record, Common Questions, How to Join a Study, and an updated Intervention/Treatment heading. Old heading 'Intervention / Treatment' and the previous revision label 'v3.5.5' were removed and replaced with the current revision 'v3.6.0'.
    Difference
    0.4%
    Check dated 2026-06-15T20:05:47.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    The page revision was updated from v3.5.4 to v3.5.5, indicating a new version of the page has been published. This appears to be a small system-level update rather than a change to the study data or its presentation.
    Difference
    0.1%
    Check dated 2026-06-08T16:46:16.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    Reid Merryman, MD has been added to the investigators list (noted on 2026-05-18 and 2026-05-04) and Philippe Armand, MD, PhD has been removed (noted on 2026-02-12, 2026-01-26, and 2023-07).
    Difference
    0.4%
    Check dated 2026-05-25T08:14:34.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.